- Home
- GLUE vs EVLV Comparison
GLUE vs EVLV Comparison
Compare GLUE & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | EVLV |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 994.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLUE | EVLV |
|---|---|---|
| Price | $10.32 | $4.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $26.88 | $9.85 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 11-17-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.18 |
| EPS | ★ N/A | N/A |
| Revenue | $123,672,000.00 | ★ $145,905,000.00 |
| Revenue This Year | N/A | $25.01 |
| Revenue Next Year | N/A | $20.02 |
| P/E Ratio | $72.42 | ★ N/A |
| Revenue Growth | ★ 63.54 | 40.48 |
| 52 Week Low | $9.68 | $4.02 |
| 52 Week High | $25.77 | $7.48 |
Technical Indicators
Market Signals| Indicator | GLUE | EVLV |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 56.36 |
| Support Level | $9.69 | $4.61 |
| Resistance Level | $12.00 | $5.21 |
| Average True Range (ATR) | 0.62 | 0.18 |
| MACD | 0.13 | 0.06 |
| Stochastic Oscillator | 54.79 | 89.09 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About EVLV Evolv Technologies Holdings Inc.
Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.